Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions.
Lawrence
D
D
Shahrokh
Z
Z
Marsters
S
S
Achilles
K
K
Shih
D
D
Mounho
B
B
Hillan
K
K
Totpal
K
K
DeForge
L
L
Schow
P
P
Hooley
J
J
Sherwood
S
S
Pai
R
R
Leung
S
S
Khan
L
L
Gliniak
B
B
Bussiere
J
J
Smith
C A
CA
Strom
S S
SS
Kelley
S
S
Fox
J A
JA
Thomas
D
D
Ashkenazi
A
A
D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D051017:Apoptosis Regulatory Proteins; D004353:Drug Evaluation, Preclinical; D022781:Hepatocytes / Q000166:cytology / Q000187:drug effects*; D006801:Humans; D066298:In Vitro Techniques; D008024:Ligands; D008252:Macaca fascicularis; D008562:Membrane Glycoproteins / Q000737:chemistry / Q000627:therapeutic use / Q000633:toxicity*; D051379:Mice; D009369:Neoplasms / Q000188:drug therapy; D011994:Recombinant Proteins / Q000737:chemistry / Q000627:therapeutic use / Q000633:toxicity; D012449:Safety; D053221:TNF-Related Apoptosis-Inducing Ligand; D014407:Tumor Cells, Cultured; D014409:Tumor Necrosis Factor-alpha / Q000737:chemistry / Q000627:therapeutic use / Q000633:toxicity*
D051017:Apoptosis Regulatory Proteins; D008024:Ligands; D008562:Membrane Glycoproteins; D011994:Recombinant Proteins; D053221:TNF-Related Apoptosis-Inducing Ligand; C505653:TNFSF10 protein, human; C505654:Tnfsf10 protein, mouse; D014409:Tumor Necrosis Factor-alpha